Average Insider

Where insiders trade, we follow

$UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Healthcare
Sector
Biotechnology
Industry
Martine A. Rothblatt
CEO
1305
Employees
$584.10
Current Price
$21.73B
Market Cap
52W Low$455.63
Current$584.1081.0% above low, 19.0% below high
52W High$614.23

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00--All Sells
Sells138$16,849,937.7928,500
2 weeksBuys00--All Sells
Sells3145$50,054,953.8385,510
1 monthBuys00--All Sells
Sells3298$116,903,327.50199,510
2 monthsBuys00--All Sells
Sells3613$230,692,002.13415,610
3 monthsBuys00--All Sells
Sells4824$325,175,057.03603,438
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 16, 2026
ROTHBLATT MARTINE A
Director
Sale514$592.05$304,312.16View Details
Nov 16, 2026
ROTHBLATT MARTINE A
Director
Sale240$593.16$142,357.87View Details
Nov 16, 2026
ROTHBLATT MARTINE A
Director
Sale200$594.60$118,920.80View Details
Nov 16, 2026
ROTHBLATT MARTINE A
Director
Sale280$582.18$163,010.37View Details
Nov 16, 2026
ROTHBLATT MARTINE A
Director
Sale640$584.54$374,103.94View Details
Nov 16, 2026
ROTHBLATT MARTINE A
Director
Sale2,108$586.72$1,236,796.06View Details
Nov 16, 2026
ROTHBLATT MARTINE A
Director
Sale835$588.59$491,474.99View Details
Nov 16, 2026
ROTHBLATT MARTINE A
Director
Sale575$590.25$339,391.39View Details
Nov 16, 2026
ROTHBLATT MARTINE A
Director
Sale170$581.25$98,812.69View Details
Nov 16, 2026
ROTHBLATT MARTINE A
Director
Sale1,382$585.83$809,620.65View Details
Nov 16, 2026
ROTHBLATT MARTINE A
Director
Sale240$583.61$140,066.02View Details
Nov 16, 2026
ROTHBLATT MARTINE A
Director
Sale1,090$587.61$640,491.96View Details
Nov 16, 2026
ROTHBLATT MARTINE A
Director
Sale110$580.25$63,827.82View Details
Nov 16, 2026
ROTHBLATT MARTINE A
Director
Sale996$591.26$588,891.47View Details
Nov 16, 2026
ROTHBLATT MARTINE A
Director
Sale120$595.19$71,422.80View Details
Nov 13, 2026
ROTHBLATT MARTINE A
Director
Sale603$589.80$355,646.51View Details
Nov 13, 2026
ROTHBLATT MARTINE A
Director
Sale518$592.61$306,973.27View Details
Nov 13, 2026
ROTHBLATT MARTINE A
Director
Sale245$593.81$145,482.91View Details
Nov 13, 2026
ROTHBLATT MARTINE A
Director
Sale528$587.42$310,156.28View Details
Nov 13, 2026
ROTHBLATT MARTINE A
Director
Sale493$588.61$290,183.05View Details

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 4, 2026
EPS
Estimated$6.18
ActualN/A
Revenue
Estimated$784.57M
ActualN/A
2 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.11.1